ES2214866T3 - Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas. - Google Patents

Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.

Info

Publication number
ES2214866T3
ES2214866T3 ES99932179T ES99932179T ES2214866T3 ES 2214866 T3 ES2214866 T3 ES 2214866T3 ES 99932179 T ES99932179 T ES 99932179T ES 99932179 T ES99932179 T ES 99932179T ES 2214866 T3 ES2214866 T3 ES 2214866T3
Authority
ES
Spain
Prior art keywords
formula
compound
carbon atoms
day
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99932179T
Other languages
English (en)
Spanish (es)
Inventor
Stanislaw R. Burzynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2214866T3 publication Critical patent/ES2214866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES99932179T 1998-07-23 1999-07-02 Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas. Expired - Lifetime ES2214866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US121567 1993-09-16
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ES2214866T3 true ES2214866T3 (es) 2004-09-16

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99932179T Expired - Lifetime ES2214866T3 (es) 1998-07-23 1999-07-02 Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.

Country Status (20)

Country Link
US (2) US6258849B1 (OSRAM)
EP (1) EP1098643B1 (OSRAM)
JP (2) JP2002521329A (OSRAM)
KR (4) KR100399658B1 (OSRAM)
CN (3) CN100400039C (OSRAM)
AT (1) ATE257378T1 (OSRAM)
AU (1) AU759278B2 (OSRAM)
BR (1) BR9912356A (OSRAM)
CA (1) CA2336945C (OSRAM)
DE (1) DE69914084T2 (OSRAM)
DK (1) DK1098643T3 (OSRAM)
EA (1) EA004179B1 (OSRAM)
ES (1) ES2214866T3 (OSRAM)
ID (1) ID28160A (OSRAM)
IL (1) IL140848A (OSRAM)
NZ (1) NZ509244A (OSRAM)
PL (1) PL213698B1 (OSRAM)
PT (1) PT1098643E (OSRAM)
WO (1) WO2000004894A2 (OSRAM)
ZA (1) ZA200100622B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
CA2420576C (en) 2000-08-29 2005-06-14 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
JP2008508300A (ja) * 2004-07-28 2008-03-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌剤としての３−ブロモ−２−オキソプロピオン酸プロピルおよび誘導体
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
HK1249434A1 (zh) 2015-08-18 2018-11-02 Ocera Therapeutics, Inc. 使用与苯乙酸盐和苯丁酸盐中的至少一种组合的l-鸟氨酸治疗和预防肌肉损失
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
IL270413B (en) 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate
IL272422B2 (en) * 2017-06-12 2025-03-01 R Burzynski Stanislaw Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
CA2254772C (en) 1996-05-14 2004-01-27 Stanislaw R. Burzynski Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
US6258849B1 (en) 2001-07-10
DE69914084T2 (de) 2004-10-28
CN1605334A (zh) 2005-04-13
HK1037142A1 (en) 2002-02-01
ZA200100622B (en) 2002-06-26
EP1098643B1 (en) 2004-01-07
CN1191064C (zh) 2005-03-02
WO2000004894A2 (en) 2000-02-03
NZ509244A (en) 2004-02-27
EA200100168A1 (ru) 2001-08-27
KR20030027088A (ko) 2003-04-03
PT1098643E (pt) 2004-05-31
KR100417100B1 (ko) 2004-02-05
CA2336945C (en) 2008-11-18
KR100414587B1 (ko) 2004-01-13
CN1319010A (zh) 2001-10-24
ID28160A (id) 2001-05-10
BR9912356A (pt) 2001-04-17
JP2002521329A (ja) 2002-07-16
IL140848A0 (en) 2002-02-10
IL140848A (en) 2005-05-17
KR20030027087A (ko) 2003-04-03
DE69914084D1 (de) 2004-02-12
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
JP2011051993A (ja) 2011-03-17
KR100417101B1 (ko) 2004-02-05
PL213698B1 (pl) 2013-04-30
US6943192B2 (en) 2005-09-13
ATE257378T1 (de) 2004-01-15
AU4854299A (en) 2000-02-14
CA2336945A1 (en) 2000-02-03
WO2000004894A3 (en) 2000-04-27
AU759278B2 (en) 2003-04-10
KR20030027089A (ko) 2003-04-03
EP1098643A2 (en) 2001-05-16
CN100400039C (zh) 2008-07-09
CN1660061A (zh) 2005-08-31
EA004179B1 (ru) 2004-02-26
DK1098643T3 (da) 2004-05-24
US20010044466A1 (en) 2001-11-22
PL345959A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
ES2214866T3 (es) Fenilacetilglutamina, fenilacetilisoglutamina y/o fenilacetato para el tratamiento de enfermedades neoplasicas.
EP1066830B1 (en) Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)
ES2425083T3 (es) Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
ES2616315T3 (es) Profármacos de ibuprofeno solubles en agua cargados positivamente con una velocidad de penetración en la piel muy rápida
ES2704848T3 (es) Agente de tratamiento y/o agente profiláctico para efectos secundarios de fármacos de cáncer
ES2312978T3 (es) Potenciador del efecto antitumoral y agente antitumoral.
WO2021074284A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
ES2280505T3 (es) Composicion farmaceutica que comprende gamma-butirobetaina.
ES2393398T3 (es) Agente reforzante del efecto antitumoral, agente antitumoral y procedimiento de terapia para el cáncer
JP2008115168A (ja) 抗アデノウイルス剤
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
US4918193A (en) Methods for preparing 3-[N-phenyl-acetylaminopiperidine]-2,6-dion
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
RU2220730C2 (ru) Способ лечения герпетического стоматита
RU2022100706A (ru) Способ лечения инсульта с применением трициклического производного
RU2003121205A (ru) Способ профилактики и (или) лечения анемии у детей (варианты)
MY145565A (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts